<iframe src="//www.googletagmanager.com/ns.html?id=GTM-MX3DVL" height="0" width="0" style="display:none;visibility:hidden"></iframe>Pestalozzi advises 3i and ten23 health in the acquisition of swissfillon AG | Pestalozzi Attorneys at Law

Pestalozzi advises 3i and ten23 health in the acquisition of swissfillon AG


Ten23 health, a pure-play, patient-centric and sustainable biologics drug product contract development and manufacturing organisation (“CDMO”), backed by 3i Group plc., acquired all shares in swissfillon AG, an FDA and Swissmedic approved drug product-focused CDMO active in the sterile filling of complex pharmaceuticals into innovative containers and devices, such as pre-filled syringes, cartridges and vials.

Pestalozzi advised 3i Group plc and its subsidiary ten23 health on all Swiss law aspects of the transaction.

The Pestalozzi team included:
Beat Schwarz (Partner - Corporate / M&A), Martin L. Mueller (Partner - Employment & Pensions), Nils Harbeke (Partner - Tax), Sarah Drukarch (Senior Associate - Life Sciences), Raphael Widmer (Associate - Corporate / M&A), Andrea P. Rohrer-Lippuner (Senior Associate - Real Estate & Environment), Florian Schnyder (Associate - Corporate / M&A), Larissa Rickenbacher (Associate - Real Estate & Environment), Hannes F. Baumgartner (Associate - Corporate / M&A), Martina Herzog (Associate - Employment), Odette Geldof (Junior Associate - Corporate / M&A)

To the top


We use cookies in order to optimally design and continuously improve our website. By continuing to use the website you consent to the use of cookies. For further information about cookies please view our data protection statement.